Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies

NCT02044861 is registered in ClinicalTrials.gov with Advanced Cancer Therapeutics as lead sponsor.

NCT NCT02044861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02044861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies
Lead sponsor
Advanced Cancer Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
March 31, 2014
Completion date
Not reported
Enrollment
56 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer